Short answer · Medically reviewed summary · Last updated: 2026-05-08
Hemimegalencephaly is a rare congenital brain malformation characterized by the overgrowth of one cerebral hemisphere, first formally described in the medical literature in the early 20th century. Over the decades, our understanding of Hemimegalencephaly has shifted from viewing it as a static structural anomaly to recognizing it as a complex, often genetic, disorder of cellular proliferation and migration. Who first described Hemimegalencephaly? While reports of unilateral brain enlargement existed in the 19th century, the term Hemimegalencephaly was solidified in the medical literature by researchers such as Sims in 1835 and later refined by clinical neuropathologists in the early 20th century.
What is the history of Hemimegalencephaly?
History of Hemimegalencephaly: when and how it was discovered, and the milestones in research since, medically reviewed.
Hemimegalencephaly is a rare congenital brain malformation characterized by the overgrowth of one cerebral hemisphere, first formally described in the medical literature in the early 20th century. Over the decades, our understanding of Hemimegalencephaly has shifted from viewing it as a static structural anomaly to recognizing it as a complex, often genetic, disorder of cellular proliferation and migration.
Who first described Hemimegalencephaly?
While reports of unilateral brain enlargement existed in the 19th century, the term Hemimegalencephaly was solidified in the medical literature by researchers such as Sims in 1835 and later refined by clinical neuropathologists in the early 20th century. Early descriptions were often based solely on post-mortem examinations, where physicians observed the striking asymmetry of the brain in patients who suffered from intractable epilepsy and severe developmental delays.
How has the understanding of Hemimegalencephaly evolved?
Historically, Hemimegalencephaly was often misdiagnosed as a tumor or a localized hypertrophy. As neuroimaging technology—specifically MRI—became the standard of care in the 1980s, clinicians could finally diagnose Hemimegalencephaly in living patients. This allowed for the realization that the condition is not just a growth issue, but a profound disruption of the mTOR signaling pathway, which controls cell growth and division.
What are the major milestones in treatment and research?
The management of Hemimegalencephaly has been transformed by the following clinical milestones:
- 1980s: The emergence of functional hemispherectomy as a surgical treatment to control life-threatening, drug-resistant epilepsy.
- 2000s: The identification of somatic mutations (notably in the PIK3CA and AKT3 genes) that cause the localized overgrowth.
- Present: The integration of advanced genetic sequencing and the development of targeted therapies aimed at the mTOR pathway.
How has patient advocacy changed the landscape?
For decades, families faced isolation due to the rarity of Hemimegalencephaly. Today, platforms like DiseaseMaps.org connect the 6 community members currently registered, providing a vital space for sharing lived experiences. This digital shift has empowered families to participate in patient-led registries, accelerating the pace of clinical research and improving access to specialized pediatric neurology centers.
Next steps
- Consult with a specialized pediatric epileptologist or neurosurgeon regarding advanced imaging and genetic testing.
- Join a supportive patient community, such as the 6 members on DiseaseMaps.org, to share resources and experiences.
- Inquire about clinical trials focusing on mTOR inhibitors for pediatric cortical malformations.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Online Mendelian Inheritance in Man (OMIM) entry for Hemimegalencephaly
- Orphanet: The portal for rare diseases and orphan drugs
- PubMed: Current literature on mTOR pathway mutations in brain malformations
